Literature DB >> 20872596

The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report.

Tuhina Neogi1, Daniel Aletaha, Alan J Silman, Raymond L Naden, David T Felson, Rohit Aggarwal, Clifton O Bingham, Neal S Birnbaum, Gerd R Burmester, Vivian P Bykerk, Marc D Cohen, Bernard Combe, Karen H Costenbader, Maxime Dougados, Paul Emery, Gianfranco Ferraccioli, Johanna M W Hazes, Kathryn Hobbs, Tom W J Huizinga, Arthur Kavanaugh, Jonathan Kay, Dinesh Khanna, Tore K Kvien, Timothy Laing, Katherine Liao, Philip Mease, Henri A Ménard, Larry W Moreland, Raj Nair, Theodore Pincus, Sarah Ringold, Josef S Smolen, Ewa Stanislawska-Biernat, Deborah Symmons, Paul P Tak, Katherine S Upchurch, Jirí Vencovský, Frederick Wolfe, Gillian Hawker.   

Abstract

OBJECTIVE: The American College of Rheumatology and the European League Against Rheumatism have developed new classification criteria for rheumatoid arthritis (RA). The aim of Phase 2 of the development process was to achieve expert consensus on the clinical and laboratory variables that should contribute to the final criteria set.
METHODS: Twenty-four expert RA clinicians (12 from Europe and 12 from North America) participated in Phase 2. A consensus-based decision analysis approach was used to identify factors (and their relative weights) that influence the probability of "developing RA," complemented by data from the Phase 1 study. Patient case scenarios were used to identify and reach consensus on factors important in determining the probability of RA development. Decision analytic software was used to derive the relative weights for each of the factors and their categories, using choice-based conjoint analysis.
RESULTS: The expert panel agreed that the new classification criteria should be applied to individuals with undifferentiated inflammatory arthritis in whom at least 1 joint is deemed by an expert assessor to be swollen, indicating definite synovitis. In this clinical setting, they identified 4 additional criteria as being important: number of joints involved and site of involvement, serologic abnormality, acute-phase response, and duration of symptoms in the involved joints. These criteria were consistent with those identified in the Phase 1 data-driven approach.
CONCLUSION: The consensus-based, decision analysis approach used in Phase 2 complemented the Phase 1 efforts. The 4 criteria and their relative weights form the basis of the final criteria set.

Entities:  

Mesh:

Year:  2010        PMID: 20872596      PMCID: PMC3077961          DOI: 10.1002/art.27580

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  5 in total

1.  2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovský; Frederick Wolfe; Gillian Hawker
Journal:  Arthritis Rheum       Date:  2010-09

Review 2.  Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis.

Authors:  Rohit Aggarwal; Katherine Liao; Raj Nair; Sarah Ringold; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2009-11-15

3.  A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis.

Authors:  F A van Gaalen; H Visser; T W J Huizinga
Journal:  Ann Rheum Dis       Date:  2005-03-30       Impact factor: 19.103

4.  The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I.

Authors:  Julia Funovits; Daniel Aletaha; Vivian Bykerk; Bernard Combe; Maxime Dougados; Paul Emery; David Felson; Gillian Hawker; Joanna M Hazes; Tom Huizinga; Jonathan Kay; Tore K Kvien; Josef S Smolen; Deborah Symmons; Paul P Tak; Alan Silman
Journal:  Ann Rheum Dis       Date:  2010-09       Impact factor: 19.103

5.  Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.

Authors:  Michael P M van der Linden; Diane van der Woude; Andreea Ioan-Facsinay; E W Nivine Levarht; Gerrie Stoeken-Rijsbergen; Tom W J Huizinga; René E M Toes; Annette H M van der Helm-van Mil
Journal:  Arthritis Rheum       Date:  2009-08
  5 in total
  87 in total

1.  Factors influencing ultrasonographic remission in patients with rheumatoid arthritis.

Authors:  Halil Harman; Ibrahim Tekeoğlu; Nedim Kaban; Sibel Harman
Journal:  Rheumatol Int       Date:  2014-11-16       Impact factor: 2.631

Review 2.  My treatment approach to rheumatoid arthritis.

Authors:  John M Davis; Eric L Matteson
Journal:  Mayo Clin Proc       Date:  2012-07       Impact factor: 7.616

3.  Improvement of large-joint ultrasonographic synovitis is delayed in patients with newly diagnosed rheumatoid arthritis: results of a 12-month clinical and ultrasonographic follow-up study of a local cohort.

Authors:  Halil Harman; İbrahim Tekeoğlu; Sibel Takçı; Ayhan Kamanlı; Kemal Nas; Sibel Harman
Journal:  Clin Rheumatol       Date:  2015-04-02       Impact factor: 2.980

4.  Pathogenetic, clinical and pharmaco-economic assessment in rheumatoid arthritis (RA).

Authors:  Gianfranco Ferraccioli; Elisa Gremese
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

5.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

Authors:  Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope
Journal:  Arthritis Rheum       Date:  2013-10-03

6.  The landscape of comparative effectiveness research in rheumatology.

Authors:  Esi Morgan DeWitt; Hermine I Brunner
Journal:  Nat Rev Rheumatol       Date:  2013-09-24       Impact factor: 20.543

7.  Mycobacterium tuberculosis lipoarabinomannan antibodies are associated to rheumatoid arthritis in Sardinian patients.

Authors:  G L Erre; D Cossu; S Masala; G Mameli; M L Cadoni; S Serdino; M G Longu; G Passiu; L A Sechi
Journal:  Clin Rheumatol       Date:  2014-05-25       Impact factor: 2.980

Review 8.  Update on outcome assessment in myositis.

Authors:  Lisa G Rider; Rohit Aggarwal; Pedro M Machado; Jean-Yves Hogrel; Ann M Reed; Lisa Christopher-Stine; Nicolino Ruperto
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

9.  sICAM-1 as potential additional parameter in the discrimination of the Sjögren syndrome and non-autoimmune sicca syndrome: a pilot study.

Authors:  Auksė Zinkevičienė; Irena Dumalakienė; Diana Mieliauskaitė; Rita Vilienė; Ieva Narkevičiūtė; Irutė Girkontaitė
Journal:  Clin Rheumatol       Date:  2019-05-31       Impact factor: 2.980

Review 10.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maxime Dougados; Paul Emery; Cecile Gaujoux-Viala; Simone Gorter; Rachel Knevel; Jackie Nam; Monika Schoels; Daniel Aletaha; Maya Buch; Laure Gossec; Tom Huizinga; Johannes W J W Bijlsma; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Cem Gabay; Juan Gomez-Reino; Marios Kouloumas; Tore K Kvien; Emilio Martin-Mola; Iain McInnes; Karel Pavelka; Piet van Riel; Marieke Scholte; David L Scott; Tuulikki Sokka; Guido Valesini; Ronald van Vollenhoven; Kevin L Winthrop; John Wong; Angela Zink; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-05-05       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.